| scholarly article | Q13442814 |
| P2093 | author name string | Paula M Vertino | |
| Dipali Sharma | |||
| Nancy E Davidson | |||
| Neeraj K Saxena | |||
| P2860 | cites work | Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation | Q22003769 |
| Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. | Q43579769 | ||
| Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor | Q43655072 | ||
| Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. | Q43755864 | ||
| Mechanism of estrogen activation of c-myc oncogene expression | Q44006970 | ||
| Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells | Q45299490 | ||
| Characterization of the proximal estrogen-responsive element of human cathepsin D gene | Q48082268 | ||
| Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase | Q71761161 | ||
| Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells | Q72386166 | ||
| Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer | Q72526379 | ||
| Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer | Q72558419 | ||
| Tamoxifen-induced apoptosis in breast cancer cells relates to down-regulation of bcl-2, but not bax and bcl-X(L), without alteration of p53 protein levels | Q73121475 | ||
| Unliganded and liganded estrogen receptors protect against cancer invasion via different mechanisms | Q73998139 | ||
| Identification and characterization of a family of mammalian methyl-CpG binding proteins | Q22003967 | ||
| Regulation of chromatin structure by site-specific histone H3 methyltransferases | Q24290115 | ||
| Purification and functional characterization of the human N-CoR complex: the roles of HDAC3, TBL1 and TBLR1 | Q24297437 | ||
| Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor | Q24311650 | ||
| Histone deacetylases and SAP18, a novel polypeptide, are components of a human Sin3 complex | Q24320470 | ||
| Ordered recruitment of histone acetyltransferases and the TRAP/Mediator complex to thyroid hormone-responsive promoters in vivo | Q24534347 | ||
| Histone deacetylases (HDACs): characterization of the classical HDAC family | Q24535587 | ||
| Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3 | Q24599788 | ||
| The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen | Q27766417 | ||
| Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins | Q27860456 | ||
| Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain | Q27860477 | ||
| The coregulator exchange in transcriptional functions of nuclear receptors | Q28131759 | ||
| Stable histone deacetylase complexes distinguished by the presence of SANT domain proteins CoREST/kiaa0071 and Mta-L1 | Q28139194 | ||
| Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor | Q28142019 | ||
| Steroid receptor coactivator-1 is a histone acetyltransferase | Q28248899 | ||
| The pharmacology and clinical uses of tamoxifen | Q28268517 | ||
| BCL-2 family members and the mitochondria in apoptosis | Q29614427 | ||
| Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer | Q29615066 | ||
| NURD, a novel complex with both ATP-dependent chromatin-remodeling and histone deacetylase activities | Q29615750 | ||
| Histone H3 lysine 4 methylation disrupts binding of nucleosome remodeling and deacetylase (NuRD) repressor complex | Q34114615 | ||
| The human histone deacetylase family | Q34119283 | ||
| Estrogen receptor interaction with estrogen response elements | Q34307898 | ||
| Mechanisms of tamoxifen-induced apoptosis | Q34398439 | ||
| Specific targeting and constitutive association of histone deacetylase complexes during transcriptional repression | Q35005873 | ||
| Estrogen receptor corepressors -- a role in human breast cancer? | Q35624506 | ||
| Towards a molecular basis for tamoxifen resistance in breast cancer | Q35674405 | ||
| Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion | Q35810732 | ||
| Activation of estrogen receptor transfected into a receptor-negative breast cancer cell line decreases the metastatic and invasive potential of the cells | Q37327536 | ||
| A nuclear hormone receptor corepressor mediates transcriptional silencing by receptors with distinct repression domains. | Q38352823 | ||
| Why are estrogen-receptor-negative breast cancers more aggressive than the estrogen-receptor-positive breast cancers? | Q40472732 | ||
| Synergistic antineoplastic action of DNA methylation inhibitor 5-AZA-2'-deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells | Q40618910 | ||
| Temporal formation of distinct thyroid hormone receptor coactivator complexes in HeLa cells | Q40837553 | ||
| Cell-specific induction of apoptosis by microinjection of cytochrome c. Bcl-xL has activity independent of cytochrome c release | Q41075236 | ||
| Tamoxifen induces TGF-beta 1 activity and apoptosis of human MCF-7 breast cancer cells in vitro | Q41208987 | ||
| Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice | Q41745394 | ||
| Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. | Q42439064 | ||
| Molecular cloning and characterization of mouse EBAG9, homolog of a human cancer associated surface antigen: expression and regulation by estrogen | Q42828645 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | estrogen | Q277954 |
| estrogen-receptor negative breast cancer | Q18553637 | ||
| tamoxifen | Q412178 | ||
| P304 | page(s) | 6370-6378 | |
| P577 | publication date | 2006-06-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes | |
| P478 | volume | 66 |
| Q37345305 | 15-LOX-1 transcription suppression through the NuRD complex in colon cancer cells. |
| Q33612962 | 5-Aza-2-deoxycytidine and trichostatin A increase COUP-TFII expression in antiestrogen-resistant breast cancer cell lines |
| Q36012225 | A Novel Combinatorial Epigenetic Therapy Using Resveratrol and Pterostilbene for Restoring Estrogen Receptor-α (ERα) Expression in ERα-Negative Breast Cancer Cells |
| Q37656483 | A chimeric SERM-histone deacetylase inhibitor approach to breast cancer therapy |
| Q38469769 | A new synthetic HDAC inhibitor, MHY218, induces apoptosis or autophagy-related cell death in tamoxifen-resistant MCF-7 breast cancer cells |
| Q35034708 | A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer |
| Q47866372 | Activation of tumor suppressor LKB1 by honokiol abrogates cancer stem-like phenotype in breast cancer via inhibition of oncogenic Stat3. |
| Q36713946 | Antiestrogen Resistance and the Application of Systems Biology |
| Q57137315 | Aromatase, aromatase inhibitors, and breast cancer |
| Q28482827 | Arsenic induces functional re-expression of estrogen receptor α by demethylation of DNA in estrogen receptor-negative human breast cancer |
| Q50115898 | BQ323636.1, a Novel Splice Variant to NCOR2, as a Predictor for Tamoxifen Resistant Breast Cancer |
| Q37576027 | Benzyl Isothiocyanate potentiates p53 signaling and antitumor effects against breast cancer through activation of p53-LKB1 and p73-LKB1 axes |
| Q37031561 | Biomarker modulation following short-term vorinostat in women with newly diagnosed primary breast cancer |
| Q91198651 | CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer |
| Q39616031 | CG0006, a novel histone deacetylase inhibitor, induces breast cancer cell death via histone-acetylation and chaperone-disrupting pathways independent of ER status |
| Q37472631 | Cancer epigenetics: a perspective on the role of DNA methylation in acquired endocrine resistance |
| Q43226742 | Cancer epigenetics: new therapies and new challenges. |
| Q38067765 | Chromatin landscape and endocrine response in breast cancer. |
| Q34547465 | Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study |
| Q39881840 | Combined inhibition of Dnmt and mTOR signaling inhibits formation and growth of colorectal cancer |
| Q35303180 | Complex prolactin crosstalk in breast cancer: new therapeutic implications |
| Q36895363 | Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells |
| Q40005351 | Cyclical DNA methylation of a transcriptionally active promoter |
| Q39542346 | Elevated expression of CUEDC2 protein confers endocrine resistance in breast cancer. |
| Q37992693 | Endocrine resistance in breast cancer: molecular pathways and rational development of targeted therapies |
| Q38741783 | Entinostat: a promising treatment option for patients with advanced breast cancer |
| Q37328845 | Epigenetic alterations in human prostate cancers. |
| Q36801625 | Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications. |
| Q38296760 | Epigenetic mechanisms of breast cancer: an update of the current knowledge |
| Q28067666 | Epigenetic polypharmacology: from combination therapy to multitargeted drugs |
| Q37024069 | Epigenetic regulation as a new target for breast cancer therapy |
| Q27694612 | Epigenetic regulation in estrogen receptor positive breast cancer--role in treatment response |
| Q37865530 | Epigenetic regulation of drug processing genes |
| Q38765639 | Epigenetic regulation of soluble guanylate cyclase (sGC) β1 in breast cancer cells |
| Q38233472 | Epigenetic reprogramming in breast cancer: from new targets to new therapies |
| Q36856318 | Epigenetic targeting in breast cancer: therapeutic impact and future direction |
| Q38459836 | Epigenetic therapy for solid tumors: from bench science to clinical trials |
| Q36449057 | Epigenetics as a therapeutic target in breast cancer |
| Q26991779 | Epigenetics in breast cancer: what's new? |
| Q37390178 | Epigenetics meets estrogen receptor: regulation of estrogen receptor by direct lysine methylation |
| Q38012175 | Epigenetics of estrogen receptor-negative primary breast cancer |
| Q37078784 | Epigenomics and breast cancer |
| Q37250659 | Estrogen Regulation of MicroRNA Expression |
| Q33705027 | Estrogen receptors recruit SMRT and N-CoR corepressors through newly recognized contacts between the corepressor N terminus and the receptor DNA binding domain |
| Q61454141 | Exploratory clinical study of chidamide, an oral subtype-selective histone deacetylase inhibitor, in combination with exemestane in hormone receptor-positive advanced breast cancer |
| Q34789970 | Functional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole |
| Q36547331 | GPER1-mediated IGFBP-1 induction modulates IGF-1-dependent signaling in tamoxifen-treated breast cancer cells |
| Q53669221 | HDAC inhibition does not induce estrogen receptor in human triple-negative breast cancer cell lines and patient-derived xenografts. |
| Q37381146 | HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2 |
| Q34352264 | Histone deacetylase inhibitors equipped with estrogen receptor modulation activity. |
| Q38838705 | Histone deacetylase inhibitors promote the expression of ATP2A3 gene in breast cancer cell lines |
| Q33563809 | Honokiol inhibits epithelial-mesenchymal transition in breast cancer cells by targeting signal transducer and activator of transcription 3/Zeb1/E-cadherin axis |
| Q39707882 | Hypermethylation of the progesterone receptor A in constitutive antiprogestin-resistant mouse mammary carcinomas. |
| Q39770073 | Influence of estradiol and triiodothyronine on breast cancer cell lines proliferation and expression of estrogen and thyroid hormone receptors |
| Q39771650 | Inhibition of histone deacetylases |
| Q35990736 | Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells |
| Q35668687 | Inhibition of skeletal metastasis by ectopic ERalpha expression in ERalpha-negative human breast cancer cell lines |
| Q36759572 | Inhibitors of histone demethylation and histone deacetylation cooperate in regulating gene expression and inhibiting growth in human breast cancer cells |
| Q53251316 | Liposomal trichostatin A: therapeutic potential in hormone-dependent and -independent breast cancer xenograft models. |
| Q35883606 | Med1 plays a critical role in the development of tamoxifen resistance |
| Q35106440 | Mitochondrial respiratory function induces endogenous hypoxia |
| Q39491094 | Novel therapeutic strategies for malignant salivary gland tumors: lessons learned from breast cancer |
| Q37529397 | Oestrogen receptor negativity in breast cancer: a cause or consequence? |
| Q30441001 | Pathways to tamoxifen resistance |
| Q34006827 | Promoting E2F1-mediated apoptosis in oestrogen receptor-α-negative breast cancer cells |
| Q37129445 | RETRACTED: Wnt-5a signaling restores tamoxifen sensitivity in estrogen receptor-negative breast cancer cells |
| Q35079955 | Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer |
| Q34994744 | Reactivation of estrogen receptor α by vorinostat sensitizes mesenchymal-like triple-negative breast cancer to aminoflavone, a ligand of the aryl hydrocarbon receptor |
| Q37655166 | Regulation of estrogen receptor signaling in breast carcinogenesis and breast cancer therapy |
| Q36878697 | SIAH2 protein expression in breast cancer is inversely related with ER status and outcome to tamoxifen therapy |
| Q35930608 | Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer |
| Q46643620 | Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor |
| Q90345723 | Shikonin and 4-hydroxytamoxifen synergistically inhibit the proliferation of breast cancer cells through activating apoptosis signaling pathway in vitro and in vivo |
| Q51365910 | Stromal-epithelial interactions modulate cross-talk between prolactin receptor and HER2/Neu in breast cancer. |
| Q36578211 | Structural and functional characterization of aromatase, estrogen receptor, and their genes in endocrine-responsive and -resistant breast cancer cells |
| Q35000289 | Subtype-specific overexpression of the Rac-GEF P-REX1 in breast cancer is associated with promoter hypomethylation. |
| Q35992790 | Survivin upregulation, dependent on leptin-EGFR-Notch1 axis, is essential for leptin-induced migration of breast carcinoma cells |
| Q89399819 | Switchable genome editing via genetic code expansion |
| Q34258435 | Synergistic epigenetic reactivation of estrogen receptor-α (ERα) by combined green tea polyphenol and histone deacetylase inhibitor in ERα-negative breast cancer cells |
| Q36688302 | Tamoxifen Action in ER-Negative Breast Cancer |
| Q37066053 | Tamoxifen resistance and epigenetic modifications in breast cancer cell lines |
| Q42344266 | Targeting tumorigenicity of breast cancer stem-like cells using combination epigenetic therapy: something old and something new |
| Q35067415 | The proteasome inhibitor bortezomib induces an inhibitory chromatin environment at a distal enhancer of the estrogen receptor-α gene |
| Q37468213 | The silent estrogen receptor--can we make it speak? |
| Q41098508 | The zinc-finger transcriptional factor Slug transcriptionally downregulates ERα by recruiting lysine-specific demethylase 1 in human breast cancer |
| Q28115934 | leptin-induced growth stimulation of breast cancer cells involves recruitment of histone acetyltransferases and mediator complex to CYCLIN D1 promoter via activation of Stat3 |
Search more.